Clinical trials: Metabolism and Elimination
Healthy Volunteers
A Mass Balance Study Following Subcutaneous Administration of [14C]-ITI-1284 to Healthy Male Subjects
ITI-1284-012 is an open-label, single-dose study to assess the mass balance recovery of radioactivity, and to evaluate the pharmacokinetics, safety and tolerability of ITI-1284 after a single subcutaneous dose of [14C]-ITI-1284…
- Trial name
- NCT06786286
- Testing
- [14C]-ITI-1284
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Intra-Cellular Therapies, Inc.
Tuberculosis
A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.
This study is a Phase 1, single-center, open-label, single-dose study to evaluate (1) the absorption, metabolism, and excretion patterns of a single dose of [14C] PA-824, and (2) the pharmacokinetics, safety, and tolerability of…
- Trial name
- CL-004 (NCT03202693)
- Testing
- PA-824
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Global Alliance for TB Drug Development
HIV Infections
Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254
This is an open-label, single-center, single group, non-randomized, two-period, single sequence, mass balance study which will enroll 6 healthy male participants.
- Trial name
- NCT04507321
- Testing
- GSK3640254 Oral tablet, [14C]-GSK3640254 intravenous infusion, [14C]-GSK3640254 powder
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy Participants
Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)
The purpose of the study is to investigate the routes of elimination and overall mass balance of 100 mg quemliclustat containing 75 μCi [14C] following a single IV infusion of [14C]-quemliclustat in healthy adult male…
- Trial name
- NCT07364214
- Testing
- Quemliclustat
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Arcus Biosciences, Inc.
Healthy
Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants
The primary objective of this study is to characterize the absorption and metabolic pathways of JNJ-63623872, and the excretion of the compound and its metabolites, after single oral dosing of 14C-JNJ-63623872 in healthy adult…
- Trial name
- NCT02448004
- Testing
- JNJ-63623872
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Janssen Cilag N.V./S.A.
Diabetes Mellitus, Type 2
A Trial to Evaluate Safety, Feasibility and Efficacy of Endoscopic Duodenal PEF Therapy
The objective of this study is to evaluate the safety, feasibility and efficacy of pulsed electric field induced duodenal mucosal regeneration (with the Endogenex System en Gen 2 Device) combined with a GLP-1 receptor agonist…
- Trial name
- EMINENT-2 (NCT05984238)
- Testing
- PEF therapy using the Endogenex Device, Semaglutide, 1.0 mg/mL
- Where
- Netherlands
- Volunteers
- 33 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Thyroid Cancer
The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients
This study will examine whether and how levothyroxine (Synthroid, a synthetic thyroid hormone) affects the way the body handles other drugs.
- Trial name
- NCT00080574
- Testing
- Skin Biopsy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Locally Advanced or Metastatic Solid Tumor
AZD5305 hADME in Patients With Advanced Solid Malignancies
This Phase I, open-label study aims to study to absolute bioavailability of Saruparib (AZD5305) and the absorption, distribution, metabolism and excretion (ADME) of [14C]-Saruparib in patients with advanced solid malignancies.
- Trial name
- AZD5305 (NCT06713369)
- Testing
- Saruparib (AZD5305), [14C]-AZD5305 microtracer, [14C]-AZD5305 (therapeutic dose)
- Where
- 2 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- AstraZeneca
Advanced Hematologic Malignancies
How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers
The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after…
- Trial name
- NCT07444268
- Testing
- DSP-5336, [14C]-DSP-5336
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sumitomo Pharma America, Inc.
Healthy Volunteer
Radiolabeled Study of CC-220 in Healthy Male Subjects
This is a single-center, open-label study to characterize the biotransformation and excretion of [14C]-CC-220 in healthy male subjects.
- Trial name
- NCT03294603
- Testing
- CC-220, [14C]
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy
Open-Label Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) Following a Single Oral Dose of AZD1236 in Healthy Male Subjects
The purpose of this study is to characterise the metabolism, excretion and pharmacokinetics of a single oral dose of [14C] AZD1236 in healthy male subjects.
- Trial name
- NCT01007929
- Testing
- 14C-AZD1236
- Where
- United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study of [14C]-LY3537982 in Healthy Participants
The main purpose of this study is to conduct blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 in healthy participants.
- Trial name
- NCT05901311
- Testing
- LY3537982, [¹⁴C]-LY3537982
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Participants
Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers
The purpose of this study is to determine the excretion kinetics and mass balance of fenebrutinib in healthy male subjects.
- Trial name
- NCT03596632
- Testing
- Fenebrutinib
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers
How [14C]-JNT-517 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Male Participants
The purpose of this study is to determine the absorption, metabolism and excretion of [14C]-JNT-517 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants following a…
- Trial name
- NCT07573449
- Testing
- [14C]-JNT-517
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy
A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants
The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it and also to assess the pharmacokinetics (PK), metabolism, and routes and…
- Trial name
- NCT05630287
- Testing
- [14C]-Selpercatinib, Selpercatinib
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Gout, Hyperuricemia
Research and Development of a New Technology for Detection of Abnormal Excretion of Intestinal Uric Acid Involved in the Incidence of Gout
To evaluate differences in specific SNPs and intestinal microflora between patients with gout and hyperuricemia and healthy controls.
- Conditions
- Gout, Hyperuricemia, Gut Microbiota, Uric Acid
- Trial name
- NCT04953533
- Testing
- no intervention
- Where
- China
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Chronic Kidney Diseases, Liver Cirrhosis
The Role of the Kidneys and Liver in the Elimination of Glucagon
The study aims to evaluate the kinetics and effect of glucagon in patients with chronic kidney disease and liver cirrhosis and matched healthy subjects, respectively.
- Conditions
- Chronic Kidney Diseases, Liver Cirrhosis, Hyperglucagonemia
- Trial name
- MCR_EndCir (NCT05056584)
- Testing
- Glucagon infusion, Primed tracer infusion
- Where
- Denmark
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Pulmonary Disease, Chronic Obstructive
A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects
Batefenterol (GSK961081) is a bifunctional bronchodilator that is being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT02663089
- Testing
- [14C]-GSK961081 solution for IV infusion, [14C]-GSK961081 oral solution, GSK961081 dry powder for inhalation
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Healthy
A Study in Healthy Men to Test How BI 1584862 is Processed in the Body
The goal of this study is to find out how BI 1584862 moves through and exits the body of healthy men. To do this, BI 1584862 is labelled using radioactive carbon (C-14) and using a non-radioactive, naturally occurring, stable…
- Trial name
- NCT07336758
- Testing
- [13C]-labeled BI 1584862, Unlabeled BI 1584862 mixed with [14C]-labeled BI 1584862
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Neuropathic Pain, Type 2 Diabetes Mellitus
Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain.
This study aimed to investigate the influence of the glycemic control of type 2 diabetes (DM2) and of cetirizine (OCTs inhibitor) on gabapentin kinetics disposition and pharmacodynamics (PK-PD) in patients with neuropathic pain.
- Conditions
- Neuropathic Pain, Type 2 Diabetes Mellitus, Diabetic Neuropathy, Painful
- Trial name
- NCT03047278
- Testing
- Serial Blood Samples, Serial Urine Samples, Gabapentin 300 mg
- Volunteers
- 29 people
- Sponsor
- Natalia Valadares de Moraes